Related Experiment Video
Updated: Nov 1, 2025
07:24
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
24.5K
SGLT2 inhibitors: What role do they play in heart failure with reduced ejection fraction?
The Nurse Practitioner
|June 17, 2021
Insights
Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce heart failure risk in type 2 diabetes. These drugs also lower cardiovascular event risk in patients with heart failure and diabetes, or heart failure alone.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Sodium-glucose cotransporter-2 (SGLT2) inhibitors are established treatments for type 2 diabetes.
- Previous research indicates SGLT2 inhibitors reduce cardiovascular events in patients with type 2 diabetes.
Purpose of the Study:
- To evaluate the efficacy of SGLT2 inhibitors in reducing cardiovascular events in patients with heart failure (HF).
- To assess the role of SGLT2 inhibitors in patients with HF and type 2 diabetes, and in patients with HF alone.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials.
- Inclusion of studies involving SGLT2 inhibitors and cardiovascular outcomes in HF populations.
Main Results:
- SGLT2 inhibitors significantly decrease the risk of heart failure in patients with type 2 diabetes.
- SGLT2 inhibitors reduce major cardiovascular events in patients with both HF and diabetes.
- Specific SGLT2 inhibitors demonstrate efficacy in reducing major cardiovascular events even in patients with HF without diabetes.
Conclusions:
- SGLT2 inhibitors offer significant cardioprotective benefits across a spectrum of patients, including those with type 2 diabetes and heart failure.
- The findings support the expanded use of SGLT2 inhibitors for cardiovascular risk reduction in heart failure patients, irrespective of diabetes status.
Abstract:
Sodium-glucose cotransporter-2 (SGLT2) inhibitors can decrease risk for heart failure in patients with type 2 diabetes and can decrease risk of major cardiovascular events in patients with heart failure (HF) and diabetes. Specific SGLT2 inhibitors can also decrease major cardiovascular events in patients with HF only.
Related Concept Videos
01:30Heart Failure V: Medical Management
60
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
60
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
632
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
632
01:22Heart Failure Drugs: Diuretics
575
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
575
01:22Heart Failure VI: Adjunct Therapies
68
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
68
01:26Heart Failure Drugs: Inotropic Agents
885
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
885
01:30Heart Failure IV: Classification and Diagnostic Evaluation
93
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
93